Shasun Pharmaceuticals has moved higher by 6% to Rs 124, also its 52-week high on the BSE, ahead of the board meeting today to consider issuing convertible warrants/equity shares on a preferential basis to the promoters.
The stock has rallied nearly 41% in the past three trading sessions from Rs 88 on April 17, after the company said that a meeting of the board of directors will be held on April 23, 2014, inter alia, for considering the issue of convertible warrants / equity shares on a preferential basis to the promoters and others. The benchmark S&P BSE Sensex has gained 2.7% during the same period.
Meanwhile, according to media reports, the company might be a beneficiary of the Sevelamer molecule drugs going off patent in the US. Shasun is expected to be one of the Active Pharmaceutical Ingredients (API) supplier of these drugs.
The counter has seen huge trading activity, with a combined 2.53 million shares changing hands till noon deals against an average sub-2 million shares that were traded daily in the past two weeks on the NSE and BSE.
The stock has rallied nearly 41% in the past three trading sessions from Rs 88 on April 17, after the company said that a meeting of the board of directors will be held on April 23, 2014, inter alia, for considering the issue of convertible warrants / equity shares on a preferential basis to the promoters and others. The benchmark S&P BSE Sensex has gained 2.7% during the same period.
Meanwhile, according to media reports, the company might be a beneficiary of the Sevelamer molecule drugs going off patent in the US. Shasun is expected to be one of the Active Pharmaceutical Ingredients (API) supplier of these drugs.
The counter has seen huge trading activity, with a combined 2.53 million shares changing hands till noon deals against an average sub-2 million shares that were traded daily in the past two weeks on the NSE and BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%